John Buse Part 7, What Do You Want Practitioners To Take Away From This Study?

In part 7 of this Exclusive Interview, John Buse urges other medical professionals to weigh the risks and benefits of using SGLT in a conversation with Diabetes in Control Publisher Steve Freed.

John Buse, PhD, MD, is professor, chief of the Division of Endocrinology, and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine.

Transcript of this video segment:

Freed:   My favorite question to end this interview is since medical professionals will be watching this, what would you like them to take away from this, because they can’t be here, when it comes to all the presentations that you’re going to be doing here?

Buse: I think the most important thing on this topic is that the SGLT-2 Inhibitors have a big effect on cardiovascular outcomes and renal outcomes in patients with type 2 diabetes, at least those who have clinical cardiovascular disease. And this concern around amputations, at least in the way that the drug is used in the population in the United States, doesn’t seem to be a problem. Now that said, in patients who have had prior amputations or who have had neuropathy, high levels neuropathy and are at risk of amputations, again, it may not be a great idea to use these drugs upfront, unless there’s a compelling indication for benefit. Like in a patient who has heart failure or in a patient who has advanced cardiovascular disease, then you really have to weigh the potential risk and benefits. And that balance, even in those patients, seems to favor the use of these drugs to prevent heart failure and hospitalizations.

Return to the main page.